MeSH term
Frequency | Condition_Probility | Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Drug Resistance, Neoplasm | 7 | 1.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Female | 12 | 0.0 |
Gene Expression | 6 | 0.0 |
Humans | 99 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 40 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Pyrimidines/*chemical synthesis/chemistry/pharmacology | 3 | 13.0 |
Research Support, U.S. Gov't, P.H.S. | 69 | 0.0 |
Structure-Activity Relationship | 16 | 0.0 |
Thymidylate Synthase/antagonists & inhibitors | 3 | 15.0 |
Models, Molecular | 2 | 0.0 |
Tetrahydrofolate Dehydrogenase/chemistry/metabolism | 2 | 40.0 |
Research Support, Non-U.S. Gov't | 54 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Transfection | 10 | 0.0 |
Catalysis | 3 | 0.0 |
Cell Line | 13 | 0.0 |
Exons | 3 | 0.0 |
Hematopoietic Stem Cells/enzymology | 3 | 13.0 |
K562 Cells | 2 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Animals | 51 | 0.0 |
Base Sequence | 15 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
Folic Acid Antagonists/pharmacology | 5 | 27.0 |
Molecular Sequence Data | 19 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Cell Division | 2 | 0.0 |
*Drug Resistance, Neoplasm | 4 | 2.0 |
Drug Screening Assays, Antitumor | 10 | 2.0 |
Tumor Cells, Cultured/drug effects | 7 | 1.0 |
Alternative Splicing | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic | 5 | 1.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Mice | 18 | 0.0 |
Peptide Synthases/*genetics | 6 | 75.0 |
Antimetabolites, Antineoplastic/*pharmacology | 8 | 8.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Folic Acid/*metabolism | 6 | 12.0 |
Folic Acid Antagonists/*pharmacology | 10 | 22.0 |
Leucovorin/therapeutic use | 2 | 14.0 |
Lung Neoplasms | 2 | 1.0 |
*Membrane Proteins | 2 | 0.0 |
*Membrane Transport Proteins | 3 | 0.0 |
Peptide Synthases/metabolism | 11 | 57.0 |
Thymidylate Synthase/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Lactobacillus casei/chemistry | 2 | 66.0 |
Rats | 10 | 0.0 |
Recombinant Proteins/antagonists & inhibitors | 2 | 4.0 |
Toxoplasma/chemistry | 2 | 66.0 |
Blotting, Western | 2 | 0.0 |
Cattle | 2 | 0.0 |
Comparative Study | 22 | 0.0 |
Cytosol/*enzymology | 2 | 3.0 |
Methotrexate/pharmacology | 4 | 4.0 |
Cytosol/enzymology | 5 | 2.0 |
In Vitro | 4 | 0.0 |
Kinetics | 15 | 0.0 |
Substrate Specificity | 13 | 0.0 |
Enzyme Inhibitors/*pharmacology | 5 | 0.0 |
Glutamates/metabolism/*pharmacology | 2 | 100.0 |
Methotrexate/metabolism/pharmacology | 2 | 33.0 |
Peptide Synthases/*metabolism | 17 | 51.0 |
Polyglutamic Acid/metabolism | 3 | 30.0 |
Antimetabolites, Antineoplastic/*pharmacokinetics/*therapeutic use | 2 | 100.0 |
gamma-Glutamyl Hydrolase/metabolism | 4 | 100.0 |
Biological Transport | 3 | 0.0 |
Cell Division/drug effects | 22 | 0.0 |
Peptide Synthases/antagonists & inhibitors/metabolism | 5 | 100.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Thymidylate Synthase/antagonists & inhibitors/metabolism | 2 | 50.0 |
Binding Sites | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Peptide Synthases/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Quinazolines/*pharmacology | 3 | 3.0 |
Thiophenes/*pharmacology | 2 | 12.0 |
Thymidylate Synthase/*antagonists & inhibitors | 9 | 47.0 |
CHO Cells | 7 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Escherichia coli/genetics | 3 | 0.0 |
Folic Acid/metabolism | 4 | 10.0 |
Hamsters | 10 | 0.0 |
Mitochondria/enzymology | 3 | 2.0 |
Peptide Synthases/genetics/*metabolism | 3 | 42.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Methotrexate/*pharmacology | 4 | 8.0 |
Peptide Synthases/*genetics/metabolism | 3 | 42.0 |
Antimetabolites, Antineoplastic/metabolism/*pharmacology | 2 | 28.0 |
Colonic Neoplasms/*enzymology/pathology | 2 | 16.0 |
Pteroylpolyglutamic Acids/*metabolism | 3 | 100.0 |
Tritium | 3 | 1.0 |
Child | 4 | 0.0 |
Child, Preschool | 2 | 0.0 |
Glutamic Acid | 2 | 2.0 |
Male | 7 | 0.0 |
gamma-Glutamyl Hydrolase/*metabolism | 2 | 40.0 |
Carcinoma, Squamous Cell | 2 | 1.0 |
Drug Synergism | 2 | 0.0 |
Head and Neck Neoplasms | 2 | 18.0 |
Adult | 2 | 0.0 |
Aged | 3 | 0.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 3 | 7.0 |
Biopsy | 2 | 0.0 |
Fluorouracil/*therapeutic use | 2 | 10.0 |
Middle Aged | 2 | 0.0 |
Thymidylate Synthase/metabolism | 3 | 14.0 |
Half-Life | 2 | 0.0 |
Rabbits | 3 | 0.0 |
DNA Primers | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Quinazolines/pharmacology | 3 | 3.0 |
Acute Disease | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Drug Design | 4 | 1.0 |
Molecular Structure | 6 | 0.0 |
gamma-Glutamyl Hydrolase/antagonists & inhibitors | 2 | 66.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Leukemia, Lymphocytic/*enzymology | 2 | 18.0 |
Leukemia | 2 | 2.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
Folic Acid Antagonists/metabolism | 2 | 40.0 |
Mice, Inbred C3H | 2 | 0.0 |
Tetrahydrofolates/metabolism | 2 | 20.0 |
Leukemia L1210/enzymology | 2 | 33.0 |
Peptide Synthases/*antagonists & inhibitors | 9 | 90.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Leucovorin/pharmacology | 4 | 40.0 |
Liver/enzymology | 7 | 1.0 |
Swine | 3 | 0.0 |
Pyrimidines/pharmacology | 2 | 1.0 |
Cells, Cultured | 7 | 0.0 |
Methotrexate/*analogs & derivatives/pharmacology/therapeutic use | 2 | 100.0 |
Tetrahydrofolate Dehydrogenase/*metabolism | 2 | 4.0 |
Chromosome Mapping | 3 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Introns | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Tetrahydrofolate Dehydrogenase/metabolism | 4 | 11.0 |
Restriction Mapping | 2 | 0.0 |
Drug Resistance | 6 | 0.0 |
Glutamates/pharmacology | 2 | 22.0 |
Guanine/analogs & derivatives/pharmacology | 2 | 15.0 |
Thiophenes/pharmacology | 2 | 5.0 |
Hypoxanthine | 3 | 25.0 |
Hypoxanthines/pharmacology | 2 | 33.0 |
Thymidine/pharmacology | 2 | 12.0 |
Acyltransferases/antagonists & inhibitors | 2 | 33.0 |
*Hydroxymethyl and Formyl Transferases | 3 | 18.0 |
Peptide Synthases/antagonists & inhibitors | 3 | 100.0 |
Time Factors | 2 | 0.0 |
Methotrexate/*metabolism/pharmacology | 2 | 100.0 |
Peptide Synthases/biosynthesis/*metabolism | 2 | 100.0 |
Polyglutamic Acid/analogs & derivatives/metabolism | 3 | 50.0 |
Escherichia coli/enzymology | 3 | 4.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Cell Survival/drug effects | 5 | 0.0 |
Escherichia coli/enzymology/genetics | 2 | 3.0 |
Carbon/*metabolism | 3 | 60.0 |
Drug Resistance/*physiology | 2 | 16.0 |
Tetrahydrofolates/*chemical synthesis/pharmacology | 2 | 100.0 |
Phenotype | 2 | 0.0 |
Chemistry | 2 | 0.0 |
Aldehyde Oxidase | 2 | 22.0 |
Liver/*enzymology | 3 | 0.0 |
Peptide Synthases/isolation & purification/*metabolism | 2 | 100.0 |
Methotrexate/analogs & derivatives | 2 | 100.0 |
Carboxypeptidases/*genetics | 2 | 9.0 |
Cricetulus | 2 | 0.0 |
